Around Rs 410 crore has been raised by Biotech startup Enzene Biosciences Ltd has secured $50 million in a fresh funding round led by its parent entity Alkem Laboratories Ltd, with participation from F-Prime Capital and Eight Roads Ventures.
Pune-based Enzene will deploy the new proceeds to boost its manufacturing capabilities and expand its footprints in India and abroad.
- Tata Motors Announced Tie-up with South Indian Bank
- Waaree Energies Received a Supply Order for 400 MW Modules
- Techno Electric Shares Hit 52-Week High on Securing Orders Worth Rs 4,000 Crore
- IREDA Shares Skyrocketed 11% on Receiving Navratna Status
- Glenmark Pharma Shares Gain 1% on Receiving USFDA Approval
Enzene Biosciences Ltd subsidiary is Alkem Labs, a novel biologics focused on producing biosimilars, phytopharmaceuticals and synthetic peptides.
Meanwhile, Mumbai-headquartered Alkem produces branded generic drugs, generics, generic drugs, nutraceuticals, and active pharmaceutical ingredients, which it markets in global markets and India.
In 2022, the Biotech space saw a spate of investments as it started garnering investors’ traction post-pandemic. In July, biotechnology company String Bio Pvt Ltd made the first closure of its Series B round after raising $20 million led by Woodside Energy, with participation from Ankur Capital, Dare Ventures, Redstart and Zenfold Ventures.